Fifteen health centers in the Málaga-Guadalhorce Health District introduce the AI agent ‘LOLA’ for chronic patient care this autumn
Up to 3,000 patients from 15 health centers in the Málaga-Guadalhorce Health District of the Andalusian Health System (SAS) will participate this autumn in the PrevAIR project, driven by the biopharmaceutical company GSK in collaboration with the technology company Tucuvi. The initiative aims to strengthen follow-up and care for patients with chronic obstructive pulmonary disease (COPD) through artificial intelligence tools.
This program incorporates the virtual clinical assistant ‘LOLA’ for COPD patient care, complementing the work of healthcare professionals with the goal of providing continuous monitoring of patients’ health status.
‘LOLA’ is an AI voice agent developed by Tucuvi, a technology company, which enables personalized and continuous monitoring of patients from their homes. While not a real person, ‘LOLA’ can convey empathy and attentiveness, listening to patients, conversing with them, and asking questions about their health status, including respiratory symptoms, to detect any changes early and report them to healthcare professionals. The program is scheduled to start this October.
This applied technology facilitates remote monitoring, early detection of warning signs, and timely intervention by healthcare professionals. Tucuvi has developed this system based on artificial intelligence and natural language processing, which has already shown positive results in other regions of Spain, being implemented in more than 10% of Spanish hospitals to support various healthcare processes. In this project, ‘LOLA’ has been implemented to improve continuous monitoring of COPD patients’ health.
The PrevAIR project aims to advance care for COPD patients by promoting a more efficient and sustainable model. By integrating digital solutions into Primary Care, the goal is to optimize healthcare resources and strengthen the connection between the health system and patients.
As Antonio Blanco, Head of Respiratory at GSK, highlights:
''This project demonstrates how AI-based technology can become an ally for professionals and patients with chronic diseases such as COPD, where personalized monitoring and attention to exacerbations are particularly important. At GSK, our commitment is to put innovation at the service of the patient.”
The use of conversational technology in healthcare has gained significant relevance in recent years, establishing itself as a useful tool both for patient support and for improving system efficiency.
With this new initiative in Málaga, GSK reaffirms its commitment to purposeful innovation, serving COPD and other respiratory disease patients, supporting healthcare professionals, and promoting a more connected, accessible, and prevention-focused health system.
Read the official press release here: https://www.sspa.juntadeandalucia.es/servicioandaluzdesalud/todas-noticia/centros-de-salud-de-malaga-participan-en-un-proyecto-de-seguimiento-de-epoc-mediante-ia
